Neuropsychological Evaluation for Early Diagnosis of PSP

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to better understand the nature of the cognitive decline in Progressive Supranuclear Palsy, the time of its development and the relation with the other cardinal features of the disease.

Detailed Description
-----------------
Progressive Supranuclear Palsy (PSP) is a neurodegenerative disease characterized by vertical supranuclear gaze palsy, early balance dysfunction and falls. Tau-protein aggregation, mainly in the brainstem, is the disease hallmark. Because of the similarities with Parkinson's disease (PD), the diagnosis is made approximately 4 years after the symptoms onset. Cognitive deficits are a leading feature of PSP and they actually represent one of the four functional core domains in the revised diagnostic criteria. The aim of this study is to better understand the nature of this cognitive decline, the time of its development and the relation with the other cardinal features of the disease.

Official Title
-----------------
The Role of the Neuropsychological Evaluation for Early Diagnosis of Progressive Supranuclear Palsy

Conditions
-----------------
Progressive Supranuclear Palsy, Cognitive Impairment

Intervention / Treatment
-----------------
* Behavioral: Cognitive evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients fulfilling the criteria for idiopathic PD Patients fulfilling the criteria for PSP Exclusion Criteria: Any other neurodegenerative disorders or medical conditions different from PD / PSP

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PSP patients<br>Patients suffering from Progressive Supranuclear Palsy (PSP) | Behavioral: Cognitive evaluation<br>* An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.<br>|
| PD Patients<br>Patients suffering from Parkinson's disease (PD) | Behavioral: Cognitive evaluation<br>* An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MMSE | Mini-Mental State Examination | 1 year | 
| FAB | Frontal Assessment Battery | 1 year | 
| MoCA | Montreal Cognitive Assessment | 1 year | 
| WCST | Wisconsin Card Sorting Test | 1 year | 
| ST | Stroop Test | 1 year | 
| TMT-A and B | Trail Making Test Parts A & B | 1 year | 
| VFT | Verbal fluency Test | 1 year | 
| ROCF copy and delayed recall | Rey-Osterrieth complex figure test copy and delayed recall | 1 year | 
| RAVLT | Rey Auditory Verbal Learning Test | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 6MWT | 6 Minute Walk Test | 1 year | 
| TUG | Timed Up and Go Test | 1 year | 
| BBS | Berg Balance Scale | 1 year |